M&A Deal Summary

OSI Pharmaceuticals Acquires Gilead Oncology Business

On December 21, 2001, OSI Pharmaceuticals acquired life science company Gilead Oncology Business from Gilead Sciences for 200M USD

Acquisition Highlights
  • This is OSI Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is OSI Pharmaceuticals’ 2nd largest (disclosed) transaction.
  • This is OSI Pharmaceuticals’ 1st transaction in the United States.
  • This is OSI Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary
Date 2001-12-21
Target Gilead Oncology Business
Sector Life Science
Buyer(s) OSI Pharmaceuticals
Sellers(s) Gilead Sciences
Deal Type Divestiture
Deal Value 200M USD

Target

Gilead Oncology Business

Foster City, California, United States
Gilead Oncology Business provides pipeline of clinical candidates in oncology and all related intellectual property.

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

OSI Pharmaceuticals

Farmingdale, New York, United States
Category Company
Founded 1983
Sector Life Science
DESCRIPTION

OSI Pharmaceuticals Inc. is an oncology drug discovery and translational research company, primarily focused on the discovery of molecular targeted therapies.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 3
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 3
Year (2001) 1 of 1
Size (of disclosed) 2 of 3
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2003-02-11 Cell Pathways

Horsham, Pennsylvania, United States

Cell Pathways, Inc develops and commercializes drugs for the prevention and treatment of cancer.

Buy $32M

Seller(S) 1

SELLER

Gilead Sciences

Foster City, California, United States

website

Category Company
Founded 1987
Sector Life Science
Employees11,000
Revenue 27.3B USD (2022)
DESCRIPTION
Entrance to Gilead Sciences' corporate headquarters in Foster City, California.
Entrance to Gilead Sciences' corporate headquarters in Foster City, California.

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was founded in 1987 and is Based in Foster City, California.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 2 of 3
Type (Divestiture) 2 of 3
State (California) 2 of 3
Country (United States) 2 of 3
Year (2001) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
1999-07-29 NeXstar Pharmaceuticals

Boulder, Colorado, United States

NeXstar Pharmaceuticals, Inc., headquartered in Boulder, Colo., is engaged in the discovery, development, manufacture, and commercialization of products to treat serious and life-threatening illnesses. NeXstar maintains additional research, development, and manufacturing facilities in San Dimas, CA, and marketing subsidiaries worldwide.

Buy $550M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2003-01-23 Triangle Pharmaceuticals

Durham, North Carolina, United States

Triangle Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing effective solutions for serious viral disease, with a particular focus on therapies for the human immunodeficiency virus (HIV), including the acquired immunodeficiency syndrome (AIDS) and the hepatitis B virus (HBV).

Buy $464M
Mergr

Product

Company

Legal